Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Amicus Therapeutics, Inc.
Amicus Therapeutics shares have gained approximately 22 percent in the past month. The company is currently collaborating with GlaxoSmithKline to develop its investigational pharmacological chaperone migalastat HCl for the treatment of Fabry disease.
Going forward ... (see research report)
Subscribe to News Feeds